FUB 181

Drug Profile

FUB 181

Latest Information Update: 08 May 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Freie Universitat Berlin
  • Developer Yamasa Corporation
  • Class Antihistamines; Neuroprotectants; Nootropics; Small molecules
  • Mechanism of Action Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cognition disorders

Most Recent Events

  • 02 Jul 2001 No-Development-Reported for Cognition disorders in Japan (Unknown route)
  • 14 Jul 1998 A preclinical study has been added to the pharmacodynamics section
  • 25 Nov 1997 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top